Compare FABC & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FABC | ALLR |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | 108 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 21.5M |
| IPO Year | 1999 | 2021 |
| Metric | FABC | ALLR |
|---|---|---|
| Price | $2.43 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 164.8K | 75.7K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,579,745.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.31 | $0.77 |
| 52 Week High | $4.57 | $1.88 |
| Indicator | FABC | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 39.68 |
| Support Level | N/A | $1.22 |
| Resistance Level | $2.98 | $1.45 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 11.82 | 14.61 |
Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.